ArriVent BioPharma, Inc. (AVBP)

NASDAQ: AVBP · Real-Time Price · USD

30.50

+0.15 (0.49%)

Jun 8, 2026, 4:00 PM EDT - Market closed

ArriVent BioPharma Earnings Call Transcripts

Fiscal Year 2025

Study Update
FV102 demonstrated significant protection against gluten-induced gut inflammation and symptoms in celiac disease, with a strong safety profile and plans for a larger phase 2 trial using composite histological and symptom endpoints.

Read full transcript →

Press release
Slides

Powered by